Funding received from Swelife for the development of a new treatment for COPD and severe asthma
Arcede Pharma AB announces that a consortium consisting of Arcede Pharma, Iconovo and Lund University has received just over SEK 2 million from Swelife.The project entitled "RCD405: New treatment paradigm for patients with COPD" receives a total of SEK 2 million to develop a dry powder formulation and an inhalation product based on the inhaler ICOone® for use in clinical phase I studies and to further characterize the mechanism of action of the drug candidate RCD405, which is intended for the treatment of COPD and severe asthma. The treatment is both bronchodilating and anti-inflammatory,